Sunnymeath Asset Management adds Eli Lilly and Co (LLY) to its portfolio

Eli Lilly and Co (LLY) : Sunnymeath Asset Management added new position in Eli Lilly and Co during the most recent quarter end. The investment management firm now holds 12,760 shares of Eli Lilly and Co which is valued at $1,024,373 , the company said in a statement filed on Jul 19, 2016 with the SEC.Eli Lilly and Co makes up approximately 1.45% of Sunnymeath Asset Management’s portfolio.

Other Hedge Funds, Including , Charter Trust Co reduced its stake in LLY by selling 1,370 shares or 1.37% in the most recent quarter. The Hedge Fund company now holds 98,592 shares of LLY which is valued at $7,914,966. Eli Lilly and Co makes up approx 0.89% of Charter Trust Co’s portfolio.Eastern Bank reduced its stake in LLY by selling 146 shares or 1.19% in the most recent quarter. The Hedge Fund company now holds 12,154 shares of LLY which is valued at $971,712. Eli Lilly and Co makes up approx 0.08% of Eastern Bank’s portfolio.West Oak Capital reduced its stake in LLY by selling 145 shares or 1.29% in the most recent quarter. The Hedge Fund company now holds 11,120 shares of LLY which is valued at $885,819. Eli Lilly and Co makes up approx 0.63% of West Oak Capital’s portfolio.First Financial Bank N.a. – Trust Division reduced its stake in LLY by selling 400 shares or 2.48% in the most recent quarter. The Hedge Fund company now holds 15,745 shares of LLY which is valued at $1,253,932. Eli Lilly and Co makes up approx 0.24% of First Financial Bank N.a. – Trust Division’s portfolio.

Eli Lilly and Co opened for trading at $80.27 and hit $80.52 on the upside on Wednesday, eventually ending the session at $80.28, with a gain of 0.39% or 0.31 points. The heightened volatility saw the trading volume jump to 28,11,087 shares. Company has a market cap of $88,616 M.

On the company’s financial health, Eli Lilly and Co reported $0.83 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Apr 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $4865.10 million for the quarter, compared to analysts expectations of $4829.37 million. The company’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS.

Investors should note that on Jun 20, 2016, Eli Lilly and Co announced a cash dividend of $0.5100. The company’s management has announced Aug 11, 2016 as the ex-dividend date and fixed the record date on Aug 15, 2016. The payable date has been fixed on Sep 9, 2016.

Many Wall Street Analysts have commented on Eli Lilly and Co. Company shares were Reiterated by Leerink Partners on May 2, 2016 to “Outperform”, Firm has raised the Price Target to $ 101 from a previous price target of $96 .

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.